[1] Tak has studied the role of the vagus nerve in chronic inflammation, work which provided the basis for clinical trials exploring bioelectronics as a novel therapeutic approach in rheumatoid arthritis patients.
In his academic life, Tak has been Visiting Professor, William Harvey Research Institute (London), Honorary Senior Visiting Fellow (University of Cambridge), Honorary Professor of Rheumatology (Ghent University) and was elected a Fellow of the Academy of Medical Sciences (U.K.) in 2016.
[5][6][7] From 2011 to 2018, Tak worked at GlaxoSmithKline as Senior Vice President, Chief Immunology Officer and Global Development Leader.
In 2018, Tak cofounded Sitryx Therapeutics with researchers Houman Ashrafian, Luke O'Neill, Jonathan Powell, Jeff Rathmell, Michael Rosenblum.
In September 2020, Tak became president and CEO of Candel Therapeutics and, in July of the following year, led the company to an Initial Public Offering (IPO) on the Nasdaq.